Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
ILT: Immunoglobulin-like transcript; KIR: Killer cell immunoglobulin-like receptor; LIR: Leukocyte immunoglobulin-like receptor; MIC: MHC class I-like; NKR: Natural killer cell receptor ...
With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...
DelveInsight's 'NK Cell Therapy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NK cell ...
Medeze Group Public Company Limited (Medeze Group), Thailand's foremost hematopoietic (HSC), mesenchymal stem cell (MSC) bank ...
T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...
Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback